Figure 3
From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection
Baseline predictors of response to natalizumab. a) A relapse in the first year was more frequent in very active patients, i.e. patients with at least 2 relapses and ≥ 1 EDSS gain in the year before starting natalizumab, *P = 0.04 b) Improvement in EDSS score after one year of treatment was not different in patients who had or had not experienced a relapse during that time; c) 1-point EDSS improvement was more frequent in patients with baseline EDSS 3.0-3.5 (§P = 0.02, univariate logistic regression); d) Patients with BET score = 1 had significantly higher pre-treatment relapse-rate compared to those with BET score = 0 (°P = 0.011).